Exelixis, Inc. is an oncology-focused biotechnology company based in Alameda, California. The company specializes in the discovery, development, and commercialization of targeted medicines for difficult-to-treat cancers. Its flagship product, cabozantinib, is a tyrosine kinase inhibitor marketed as CABOMETYX for advanced renal cell carcinoma and hepatocellular carcinoma, and as COMETRIQ for progressive, metastatic medullary thyroid cancer. Additionally, Exelixis partnered with Roche to bring Cotellic (cobimetinib) to market for the treatment of specific forms of advanced melanoma. Originally founded on functional genomics research, the company has evolved into a commercial-stage enterprise with a pipeline of targeted small-molecule therapies and biologics. Exelixis primarily commercializes its products in the United States while leveraging strategic partnerships with global pharmaceutical companies to distribute its therapies internationally.
